NCT00256126 - Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® | Biotech Hunter

Enrollment

318

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Growth Hormone DeficiencyTurner Syndrome

Interventions

DRUG

Saizen

Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month

DRUG

Saizen

Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.

Trial Locations (13)

Unknown

Local Medical Information Office, Buenos Aires

Local Medical Information Office, Sydney

Local Medical Information Office, Vienna

Local Medical Information Office, Mississauga

Local Medical InformationOffice, Paris

Local Medical Information Office, Munich

Local Medical Information Office, Rome

Local Medical Information Office, Oslo

Local Medical Information Office, Russia

Local Medical Information Office, Singapore

Local Medical Information Office, Madrid

Local Medical Information Office, Stockholm

Local Medical Information Office, Feltham

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY